香砂六君子贴敷联合昂丹司琼在预防和治疗mFOLFOX6方案化疗后不良反应的临床研究

Abstract
Figure/Table
References
Related Citation (3)

Download: PDF (2109 KB) HTML (0 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective This study was designed to evaluate the clinical efficacy and toxic side effect of Xiangsha Liujunzi paste applied to the Shenque acupoint in combination with Ondansetron in preventing and treating nausea, vomiting, and appetite loss caused by the mFOLFOX6 chemotherapy regimen. The goal of this study was to provide scientific evidence for the integration of traditional Chinese and Western medicine in treating vomiting induced by gastric cancer chemotherapy. Methods A prospective randomized controlled trial design was employed in this study. Sixty patients who underwent radical surgery for gastric cancer with the mFOLFOX6 chemotherapy regimen were selected as subjects and randomly assigned to the control group and the treatment group. The control group received Ondansetron (8mg Q12h intravenously) on days 1, 2, and 3 of chemotherapy, while the treatment group underwent additional Shenque acupoint application treatment daily from day 1 to day 7 of chemotherapy, lasting 24 hours. Observation indicators included the incidence of nausea, acute vomiting, appetite loss during the first three days of two chemotherapy cycles, delayed vomiting on day four of chemotherapy, and Karnofsky performance scores before and after two cycles. Results The treatment group showed a higher incidence of mild (grade 0-I) nausea on days 1, 2, and 3 after the first and second cycles of chemotherapy compared to the control group, with a statistically significant difference. The effectiveness of acute vomiting treatment was also significantly higher in the treatment group. In terms of the delayed vomiting, the incidence was significantly lower in the treatment group, with a statistically significant difference. Additionally, the treatment group demonstrated a higher effectiveness in treating appetite loss compared to the control group, with a statistically significant difference. Regarding Karnofsky performance scores, both groups experienced declines, but the difference before and after chemotherapy in the treatment group was not significant, whereas it was significant in the control group; the difference between the two groups after treatment was also significant. Conclusion The combination of Xiangsha Liujunzi paste application and Ondansetron can effectively prevent and treat negative symptoms of nausea, vomiting, and appetite loss induced by the mFOLFOX6 chemotherapy regimen, and it also improves the quality of life for patients with gastric cancer. These findings provide new insights and strategies for integrating traditional Chinese and Western medicine in treating chemotherapy-related side effect.

Key words： chemotherapy-induced nausea and vomiting gastric cancer ondansetron acupuncture therapy

Received: 29 May 2024

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	NING Zhi
	ZHOU Dai
	DAI Xingjun
	WANG Dan
	WU Minghui
	PENG Yue
	LI Cuiying

Cite this article:

NING Zhi,ZHOU Dai,DAI Xingjun等. Clinical Study on the Prevention and Treatment of Negative Effect after mFOLFOX6 Chemotherapy Protocol using a Combination of Xiangsha Liujunzi Paste and Ondansetron[J]. HuNan ShiFan DaXue XueBao(YiXueBan), 2024, 21(4): 145-149.

URL:

http://yxb.hunnu.edu.cn/EN/ OR http://yxb.hunnu.edu.cn/EN/Y2024/V21/I4/145

[1] 王少明, 郑荣寿, 韩冰峰, 等.2022年中国人群恶性肿瘤发病与死亡年龄特征分析[J]. 中国肿瘤, 2024, 33(03): 165-174.
[2] FERLAY J, ERVIK M, LAM F, et al.Global cancer observatory: cancer today[EB/OL].[2024-01-31].https://gco.iarc.fr/today
[3] ZENG H, CHEN W, ZHENG R, et al.Changing cancer survival in China during 2003 -15: a pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health, 2018, 6(5): e555-e567.
[4] 刘俊俊. 胃癌化疗患者营养状况与化疗期间不良反应及生活质量的相关性分析[J]. 黑龙江医学, 2023, 47(21): 2661-2663.
[5] MOSA A, HOSSAIN A M, LAVOIE B J, et al.Patient-Related Risk Factors for Chemotherapy-Induced Nausea and Vomiting: ASys- tematic Review[J]. Front Pharmacol, 2020, 11: 329.
[6] 郭芷君, 徐峰. 化学治疗所致恶心呕吐分类与药物治疗的研究进展[J]. 中国药业, 2020, 29(22): 1-6.
[7] 韩斯宇, 廖秀秀, 赵耀中, 等. 中医药防治化疗性恶心呕吐的CiteSpace知识图谱分析[J]. 广东药科大学学报, 2023, 39(02): 94-105.
[8] 曹兆铭, 孙文静, 李萍, 等. 铂类化疗药物所致恶心呕吐的预防及治疗进展[J]. 护理实践与研究, 2021, 18(18): 2721-2727.
[9] 周建超, 张晴. 治疗铂类药物所致呕吐的成本效果分析[J]. 中国医院用药评价与分析, 2016, 16(S1): 116.
[10] 胡中韦, 黄伟, 司海龙, 等. 化疗相关性呕吐的中西医治疗进展[J]. 辽宁中医杂志, 2020, 47(10): 217-221.
[11] 李满, 冯瑞红, 邢通, 等. 化疗所致恶心、呕吐防治药物的应用情况[J]. 河南医学研究, 2021, 30(12): 2163-2166.
[12] 丁兰萍. 中药治疗恶性肿瘤化疗后胃肠道反应的Meta分析与用药规律探究[D]. 长春:长春中医药大学, 2022.
[13] 国文文. 中药治疗恶性肿瘤化疗后消化道反应的用药规律研究[D]. 北京:北京中医药大学, 2021.
[14] National Comprehensive Cancer Network. NCCN Clini-cal Practice Guidelines in Oncology, Antiemesis v.1.[EB/OL].[2023-01-17]. http://ww.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf.
[15] CUPISSOL D.Proc 5th Euro Conf Clin oncol London 1990Smith Kline Beecham Satellite Symposium[J]. Euro J Cancer, 1990, 26(Suppl1): 22.
[16] 胡小艳, 段盈芳, 梁欢, 等. 化疗相关性恶心呕吐高危风险评估工具的研究进展[J]. 护士进修杂志, 2021, 36(10): 895-898.
[17] 王妍, 刘天舒.2021年胃癌药物治疗盘点[J]. 实用肿瘤杂志, 2022, 37(02): 107-111.
[18] 程海波, 贾立群. 中西医结合肿瘤学[M]. 北京: 中国中医药信息出版社, 2023.
[19] 王龙, 吴朝君, 王丽曼, 等. 个体化诊疗模式在胃肠道恶性肿瘤中预防中度致吐性化疗方案的临床观察[J]. 中国肿瘤临床, 2021, 48(05): 235-242.
[20] 杨玲, 夏超, 杨丽萍, 等. 子午流注针法联合托烷司琼预防胃癌患者铂类化疗所致恶心呕吐的临床研究[J]. 天津护理, 2022, 30(01): 98-101.
[21] 刘永胜. 胃癌化疗后脾胃虚弱证患者应用香砂六君子汤的治疗价值[J]. 深圳中西医结合杂志, 2021, 31(03): 62-64.
[22] 唐潇然, 呼健, 赵鹏飞. 香砂六君子汤加减对胃癌患者术后肠黏膜屏障及免疫状态的影响[J]. 中国医药, 2023, 18(12): 1874-1878.
[23] 姜蕾, 孙晓红, 王秀. 中医脐疗的现代临床进展简述[J]. 基层中医药, 2023, 2(06): 132-137.
[24] 任晓琴, 吴雪元. 外用止吐方配合穴位贴敷疗法治疗消化道恶性肿瘤化疗相关恶心、呕吐的临床观察[J]. 内蒙古中医药, 2020, 39(06): 113-114.
[25] 章燕. 穴位注射配合脐疗干预原发性胃癌化疗后恶心呕吐临床观察[J]. 中国民间疗法, 2016, 24(04): 45-46.